Neurogene Inc. NGNE
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
11.14
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $0 | -$90.4M | — | -$78.4M | $264.9M |
| 2024 | $925,000 | -$75.1M | — | -$71.4M | $310.4M |
| 2023 | $0 | -$36.3M | — | -$51.7M | $186.0M |
| 2022 | — | -$55.2M | — | -$55.1M | -$145.7M |
| 2021 | — | -$60.7M | — | -$50.8M | -$91.9M |
| 2020 | — | -$33.3M | — | -$26.8M | $191.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Cvijic Christine Mikail | President and CFO | 2026-05-06 | Sell | 4,800 | $30.07 |
| Cvijic Christine Mikail | President and CFO | 2026-05-06 | Sell | 4,800 | $32.44 |
| Cvijic Christine Mikail | President and CFO | 2026-03-26 | Sell | 2,558 | $21.62 |
| McMinn Rachel | Chief Executive Officer | 2026-03-26 | Sell | 3,352 | $22.07 |
| Jordan Julie | Chief Medical Officer | 2026-03-26 | Sell | 828 | $21.89 |
| Cobb Stuart | Chief Scientific Officer | 2026-03-13 | Sell | 3,991 | $20.41 |
| Cobb Stuart | Chief Scientific Officer | 2026-03-13 | Sell | 2,658 | $21.34 |
| Cobb Stuart | Chief Scientific Officer | 2026-03-13 | Sell | 148 | $22.08 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 11.14 (safe)
- Working capital / assets 0.885
- Retained earnings / assets -1.222
- EBIT / assets -0.358
- Equity / liabilities 11.169
Source: SEC EDGAR filings · CIK 0001404644 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.